Lys-Pro-Val
Evidence Grade C — Moderate human evidence. 64 published studies, 35 human. 0 registered clinical trials.
KPV is a synthetic tripeptide made from the three end amino acids of alpha-MSH, a natural hormone involved in inflammation control. It has no approval from any regulatory agency and no human clinical trials have been conducted. The evidence consists entirely of cell culture studies and mouse models of intestinal inflammation.
64 published studies: 35 human, 18 animal, 10 in-vitro, 8 reviews
KPV has no marketing authorisation from any regulatory agency. No human clinical trials have been conducted. The preclinical evidence consists of cell culture studies and mouse models of colitis.
The absence of human safety data, pharmacokinetic data, dosing studies, and efficacy trials means that KPV's effects in humans are entirely uncharacterised. Products available through unregulated channels lack pharmaceutical quality assurance.
Research in cell culture and animal models suggests KPV may reduce inflammatory signalling, potentially through inhibition of the NF-kappaB pathway. Unlike its parent molecule alpha-MSH, KPV does not appear to activate melanocortin receptors, meaning it does not affect pigmentation or appetite pathways. These observations are from preclinical studies only and have not been confirmed in humans.
Research in animal models and cell cultures suggests KPV may reduce inflammatory signalling, potentially through pathways different from its parent molecule alpha-MSH. Unlike alpha-MSH, it does not appear to affect pigmentation or appetite. No human safety data, pharmacokinetic data, dosing studies, or efficacy trials exist. The compound's effects in humans are entirely unknown. As a tripeptide, it is likely rapidly degraded by enzymes in the body, raising questions about bioavailability after injection. Products from unregulated sources lack pharmaceutical quality assurance.
No trials registered on ClinicalTrials.gov for this compound.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Corticotropin is marketed as H.P. Acthar Gel (currently ANI Pharmaceuticals). It carries approximately 19 FDA-labelled indications including infantile spasms (its strongest evidence base), nephrotic syndrome, multiple sclerosis relapses, and rheumatic disorders. Acthar Gel has been at the centre of major pricing and legal controversies. The price rose from approximately $40 per vial in 2001 to over $40,000, driven by successive acquisitions and orphan-like positioning despite broad labelling. The former manufacturer Mallinckrodt agreed to a $260 million settlement over antitrust concerns. Clinically, the strongest evidence supports its use in infantile spasms, where it is considered a first-line treatment. For most other indications, debate continues over whether it offers meaningful advantages over far less expensive oral corticosteroids.
Enfuvirtide is marketed as Fuzeon (approved March 2003). It requires twice-daily subcutaneous injections, and injection-site reactions occur in nearly all patients (98%). In clinical trials (TORO-1 and TORO-2), enfuvirtide combined with an optimised background regimen achieved significantly greater viral suppression than background regimen alone in treatment-experienced patients. Enfuvirtide represented a major advance when HIV drug resistance was a more pressing clinical challenge, but its use has declined substantially with the arrival of more convenient oral antiretrovirals. The twice-daily injection burden, injection-site reactions, high cost, and complex manufacturing (it is one of the largest synthetic peptides manufactured at scale) have limited its role to a last-resort option for patients with highly resistant HIV.
Vancomycin is marketed as Vancocin and Firvanq (approved 1958, with oral solution Firvanq approved 2018). It is the standard treatment for serious MRSA infections (bloodstream infections, endocarditis, pneumonia, bone infections) and is first-line for severe C. difficile colitis. Vancomycin requires therapeutic drug monitoring — blood levels must be checked regularly to ensure the dose is effective without causing kidney damage or hearing loss. The rise of vancomycin-resistant enterococci (VRE) and occasional vancomycin-intermediate S. aureus (VISA) strains represent ongoing challenges. Despite being nearly 70 years old, vancomycin remains irreplaceable for many serious infections, though newer alternatives like daptomycin and the lipoglycopeptides offer advantages in specific settings.
